Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | PIK3C3 | Q8NEB9 | 11/20 | 0.50 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29899021 | 1.00 | L3MBTL1 (0.55) | L3MBTL1PIK3C3RIOK2JAK2JAK1 | |
| Ammonia Solution, Strong SCHEMBL28494689 | 0.98 | L3MBTL1 (0.53) | L3MBTL1PIK3C3RIOK2JAK2JAK1 | |
| SCHEMBL477127 | 0.83 | SMN1; SMN2 (0.53) | L3MBTL1RIOK2NTRK1SORT1SMN1; SMN2 | |
| SCHEMBL16913891 | 0.83 | RIOK2 (0.56) | L3MBTL1RIOK2NTRK1SORT1SMN1; SMN2 | |
| SCHEMBL30185638 | 0.82 | JAK2 (0.51) | L3MBTL1PIK3C3RIOK2JAK2JAK1 | |
| SCHEMBL21752721 | 0.82 | ALDH1A1 (0.44) | L3MBTL1PIK3C3RIOK2NTRK1SORT1 | |
| SCHEMBL16923772 | 0.82 | JAK2 (0.51) | L3MBTL1PIK3C3RIOK2JAK2JAK1 | |
| SCHEMBL1505643 | 0.82 | JAK2 (0.54) | L3MBTL1RIOK2JAK2JAK1TYK2 | |
| SCHEMBL19478462 | 0.81 | RIOK2 (0.43) | L3MBTL1PIK3C3RIOK2NTRK1SORT1 | |
| SCHEMBL25240657 | 0.81 | LMNA (0.49) | L3MBTL1RIOK2NTRK1SORT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035349-A1 | 3,4-alkoxy Substituted Phenethyl Lactam Compound, Preparation Method therefor, and Use Thereof | GUANGZHOU CHIA TAI INNOVATIVE PHARMACEUTICAL CO., LTD. (CN) | 2026-02-05 | — | — | US | disclosed |
| EP-4619099-A1 | PYRIDO OXAZOLIDINONE DERIVATIVES AS ALK5 INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-09-24 | — | — | EP | disclosed |
| EP-4578852-A1 | HETEROCYCLIC COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-07-02 | — | — | EP | disclosed |
| US-20250188075-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | THE BROAD INSTITUTE, INC. | 2025-06-12 | — | — | US | disclosed |
| EP-4509122-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2025-02-19 | — | — | EP | disclosed |
| US-20240425482-A1 | PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-12-26 | — | — | US | disclosed |
| EP-4188551-B1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-12-18 | — | — | EP | disclosed |
| EP-4469457-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | The Broad Institute Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240360131-A1 | BIARYL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-10-31 | — | — | US | disclosed |
| US-20240360134-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2024-10-31 | — | — | US | disclosed |
| WO-2011076725-A1 | THIENYLPYRI (MI) DINYLAZOLE AND THEIR USE FOR CONTROLLING PHYTOPATHOGENIC FUNGI | BAYER CROPSCIENCE AG (DE) | 2011-06-30 | — | — | WO | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003806-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20100331326-A1 | Inhibitors of CYP 17 | NOVARTIS AG | 2010-12-30 | — | — | US | disclosed |
| US-20100256172-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256172-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256172-A1 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010090716-A1 | HETEROARYLS AND THEIR USE AS PI3K INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360134-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | PDGFRB, PDGFRA, ABL1 | L3MBTL1 4865/4885PIK3C3 96/4885RIOK2 919/4885 |
| US-20240425482-A1 | PYRROLIDINE DERIVATIVES AS DDRS INHIBITORS | DDR1, DDR2, DDRGK1 | L3MBTL1 3733/4885PIK3C3 977/4885RIOK2 1532/4885 |
| US-20100331326-A1 | Inhibitors of CYP 17 | CYP17A1, CYP21A2, CYP4A22 | L3MBTL1 4701/4885PIK3C3 838/4885RIOK2 1699/4885 |
| US-20260035349-A1 | 3,4-alkoxy Substituted Phenethyl Lactam Compound, Preparation Method therefor, and Use Thereof | CES1, CYP51A1, PDE3A | L3MBTL1 2959/4885PIK3C3 1265/4885RIOK2 2016/4885 |
| US-20110003806-A1 | Heteroaryls and uses thereof | RICTOR, MTOR, AKT1S1 | L3MBTL1 1465/4885PIK3C3 61/4885RIOK2 846/4885 |
| US-20100256172-A1 | Heteroaryls and uses thereof | PIK3R3, PIK3R1, AKT3 | L3MBTL1 3009/4885PIK3C3 20/4885RIOK2 535/4885 |
| US-20240360131-A1 | BIARYL KINASE INHIBITORS | AAK1, NCK1, MARCKS | L3MBTL1 1330/4885PIK3C3 424/4885RIOK2 549/4885 |
| US-20250188075-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | CSNK1A1, CSNK2A1, CSNK1A1L | L3MBTL1 3661/4885PIK3C3 1905/4885RIOK2 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.